Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
about
Clinical management of infections caused by multidrug-resistant EnterobacteriaceaeComparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosaPhase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult SubjectsStrategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious DiseasesMeropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.Pharmacodynamics of antimicrobials: treatment optimisation.Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?Pharmacodynamic optimization of beta-lactams in the patient care setting.A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure.Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections.Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics Vaborbactam and Meropenem Alone and in Combination Following Single and Multiple Doses in Healthy Adult Subjects.Meropenem-Vaborbactam: Single-Dose Pharmacokinetics and Safety in Subjects with Chronic Renal Impairment.
P2860
Q28246841-46F67C3A-52C0-43C0-9E3C-6233DFF2457CQ33722108-868FD169-074F-43DC-A872-D4821DD10D6DQ34228382-F91CAC85-E295-4092-8C5C-21848F509B5CQ34537388-F4084659-9B4B-4BF4-8F69-F4F59A0117E0Q35986250-44A66D5B-1FA2-4FA6-A429-3E3CFD50BDF2Q36290773-76257191-497A-49CC-921E-A55F2F936ACBQ36544935-5B609E1A-C406-461A-BAEB-513B5EB6E07CQ37146405-522A7DEE-1B3B-4B31-B55D-AB2A62148E94Q37169843-3A684CBA-CF48-4880-81D9-93BA4C93B350Q39665401-513123DB-AE87-4A93-9198-088F99C6AA93Q43733954-F1A9307D-3146-4C02-B783-99247F93EB8FQ44601141-281F79D3-DBFE-4942-B8D8-BBDD0A0227FBQ45954223-C946B9F4-9DDA-4887-8499-39D9B30D70A8Q46921577-79E9D3C0-801D-4375-9CF8-B7813E41B862Q47647043-A83B487D-C777-4EAB-94CF-921BF3E5E860Q50044367-53D975B0-5278-4B3C-ACDE-1F2FD404FFBEQ50114942-615E1BE2-4DCF-4D5A-B017-3E8F7AD3A0DE
P2860
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
@en
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
@nl
type
label
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
@en
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
@nl
prefLabel
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
@en
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
@nl
P2093
P2860
P1433
P1476
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
@en
P2093
Charles H Nightingale
Christina A Sutherland
Dana Maglio
David P Nicolau
Prachi K Dandekar
P2860
P304
P356
10.1592/PHCO.23.8.988.32878
P407
P577
2003-08-01T00:00:00Z